NEUROMED

Neuromed specializes in electrophysiological monitoring devices. These include portable and fixed EEG (electroencephalography) systems like the Evidence EEG series (models 61, 63, 64, and 65) and the Litebox. The company also produces neuromonitoring tools such as the Neuron-Spectrum series (models 61, 62, 63, 64, and 65) and the Neuromonitor. These devices are designed for clinical and research use in neurology and neuroscience, focusing on brain activity monitoring and related diagnostics.

Neuromed is based in France, which places its devices under the regulatory framework of the European Union. Since these devices are classified as Class IIa, they must comply with EU Medical Device Regulations (MDR) or previous Directives (MDD), including mandatory registration in the EUDAQMED database. The company’s location ensures alignment with EU standards for safety, performance, and traceability of its medical devices.

Neuromed’s devices are listed in the EUDAQMED database, the official EU registry for medical devices. This registration is critical because it demonstrates compliance with EU requirements for device traceability, transparency, and market surveillance. It allows healthcare professionals, regulators, and authorities to verify the device’s legal status and regulatory history within the European market.

Neuromed’s devices fall under EU Class IIa classification, which indicates a moderate risk level requiring additional scrutiny beyond basic safety checks. This classification means the devices undergo rigorous conformity assessments, including clinical evaluations and technical documentation reviews, to ensure their safety and performance. Class IIa devices are permitted for use in clinical settings but require adherence to stricter regulatory controls compared to lower-risk classes.